Tower Research Capital LLC (Trc) Mi Nk Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 8,947 shares of INKT stock, worth $6,710. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,947
Previous 11,060
19.1%
Holding current value
$6,710
Previous $10,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
901KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$175,6360.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$124,9990.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$95,8800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$72,2600.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$65,3970.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $25.3M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...